Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Entyvio Takes Lead As Takeda Pursues Turnaround

Executive Summary

Takeda’s CEO says the company is continuing to deliver on its turnaround plan after a stronger first half, with Entyvio providing much of the momentum for the underlying growth and a brighter full-term outlook.

You may also be interested in...



Takeda Enlists Real World Evidence To Boost Marketed Entyvio

Japan’s Takeda says it has confirmed the benefits of its best-selling inflammatory bowel disease therapy Entyvio in US medical practice through the collection of real world evidence.

Takeda Closing In Again On Valeant Assets?

Takeda and Valeant are rumored to have restarted talks over some form of potential deal, this time reportedly focusing on a possible offer by the Japanese firm for Valeant's gastrointestinal business unit Salix.

New Bridge Venture Aligns With Takeda Externalization Strategy

A new collaborative academic-industry medicines development venture involving Takeda has started operations in the US, aiming to smooth and speed the passage of basic research projects through clinical trials and eventually to the market.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC097570

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel